Ozempic and Wegovy: Psychiatric Side Effects and What to Watch For

Ozempic (semaglutide 0.5-2 mg, for type 2 diabetes) and Wegovy (semaglutide 2.4 mg, for weight management) are the same active molecule at different doses. As GLP-1 receptor agonists, they act on brain receptors involved in appetite, reward, and mood regulation. Most patients tolerate semaglutide well psychiatrically, but awareness of potential neuropsychiatric effects is important for informed care.

Commonly reported (in clinical trials and post-marketing):

• Changes in appetite relationship with food ('food noise' reduction)
• Fatigue and low energy (especially during dose titration)
• Insomnia or sleep changes
• Irritability during initial weeks

Less commonly reported (post-marketing surveillance):

• Depressed mood or new onset depression
• Anxiety
• Suicidal ideation (under regulatory review — no causal link established)
• Reduced motivation or apathy
• Changes in alcohol tolerance or desire

It is important to note that weight loss itself — from any method — can trigger mood changes, particularly in individuals with a history of mood disorders.

Certain populations may need closer psychiatric monitoring when starting semaglutide:

• History of depression or bipolar disorder — mood episodes can be triggered by metabolic changes, rapid weight loss, or dietary shifts
• History of eating disorders — appetite suppression may mask restrictive patterns; rapid body changes may trigger body image disturbance
• Current use of psychiatric medications — weight loss changes drug pharmacokinetics; GI side effects (nausea, vomiting) may affect oral medication absorption
• History of suicidal ideation — while no causal link is established, additional monitoring is prudent
• Substance use disorders — reward circuitry modulation may have unpredictable effects, though early evidence suggests potential benefit

Semaglutide slows gastric emptying, which can affect absorption timing of oral medications. Psychiatric medications that may be affected include:

• Lithium — narrow therapeutic index; GI effects and dehydration from semaglutide may alter lithium levels. Monitor levels closely.
• Oral antipsychotics — delayed absorption may reduce peak concentrations. Extended-release formulations may be particularly affected.
• Benzodiazepines and Z-drugs — fat-soluble medications may have increased effective concentrations as body fat decreases.
• Mood stabilizers (valproate, carbamazepine) — weight-dependent dosing and GI effects warrant level monitoring.
• Stimulants (ADHD medications) — combined appetite suppression may lead to excessive weight loss; monitor weight and nutritional status.

If you or someone you know starts semaglutide, monitor for these changes in the first 3-6 months:

• Sustained changes in mood lasting more than 2 weeks (not just a bad day)
• New or worsening anxiety that isn't related to GI side effects
• Loss of interest in activities beyond food (anhedonia)
• Sleep disruption that persists beyond dose titration
• Any suicidal thoughts — seek immediate help
• Significant changes in how psychiatric medications feel or work

These warrant a conversation with your prescriber, not necessarily stopping the medication.

For many patients, semaglutide improves psychiatric well-being through multiple pathways: weight loss improves self-esteem, mobility, sleep apnea, and chronic pain — all of which affect mood. Reduced systemic inflammation (obesity is pro-inflammatory) may directly benefit depression. Better metabolic health improves energy and cognitive function. Some patients describe the reduction in 'food noise' — constant preoccupation with food — as mentally freeing. The emerging addiction data suggests potential direct neuropsychiatric benefits beyond weight loss.